The neurotrophins and their role in Alzheimer's disease

Current Neuropharmacology

Volumn 9, Issue 4, 2011, Pages 559-573

  Allen, Shelley J ^a   Watson, Judy J ^a   Dawbarn, David ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Alzheimer's disease; BDNF; Cholinergic basal forebrain; NGF; Synaptic plasticity

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; NEUROTROPHIC FACTOR; RECOMBINANT NERVE GROWTH FACTOR;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; FIBROBLAST; FOREBRAIN; HIPPOCAMPUS; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NERVE CELL; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; NONHUMAN; REVIEW;

EID: 82955192655     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015911798376190     Document Type: Review

References (181)

1. Brookmeyer, R.; Johnson, E.; Ziegler-Graham, K.; Arrighi, H. M. Forecasting the global burden of Alzheimer's disease. Alzheimers. Dement., 2007, 3(3), 186-191.
2. Alzheimer, A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie Psychisch-Gerichtlich Medizine, 1907, 64, 146-148.
3. Pearson, R. C.; Esiri, M. M.; Hiorns, R. W.; Wilcock, G. K.; Powell, T. P. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1985, 82(13), 4531-4534.
4. Saper, C. B.; German, D. C.; White, C. L., III. Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer's type: possible role in cell loss. Neurology, 1985, 35(8), 1089-1095.
5. Braak, H., Braak, E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol., 1991, 82(4), 239-259.
6. Dekosky, S. T., Scheff, S. W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol., 1990, 27(5), 457-464.
7. Allen, S. J., Dawbarn, D. Clinical relevance of the neurotrophins and their receptors. Clin. Sci. (Lond), 2006, 110(2), 175-191.
8. Sims, N. R.; Bowen, D. M.; Allen, S. J.; Smith, C. C.; Neary, D.; Thomas, D. J.; Davison, A. N. Presynaptic cholinergic dysfunction in patients with dementia. J. Neurochem., 1983, 40(2), 503-509.
9. Davies, P., Maloney, A. J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet, 1976, 2(8000), 1403-
10. Perry, E. K.; Perry, R. H.; Gibson, P. H.; Blessed, G.; Tomlinson, B. E. A cholinergic connection between normal aging and senile dementia in the human hippocampus. Neurosci. Lett., 1977, 6(1), 85-89.
11. Dekosky, S. T.; Harbaugh, R. E.; Schmitt, F. A.; Bakay, R. A.; Chui, H. C.; Knopman, D. S.; Reeder, T. M.; Shetter, A. G.; Senter, H. J.; Markesbery, W. R. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group. Ann. Neurol., 1992, 32(5), 625-632.
12. Rinne, J. O.; Kaasinen, V.; Jarvenpaa, T.; Nagren, K.; Roivainen, A.; Yu, M.; Oikonen, V.; Kurki, T. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 2003, 74(1), 113-115.
13. Counts, S. E., Mufson, E. J. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J. Neuropathol. Exp. Neurol., 2005, 64(4), 263-272.
14. Dekosky, S. T.; Ikonomovic, M. D.; Styren, S. D.; Beckett, L.; Wisniewski, S.; Bennett, D. A.; Cochran, E. J.; Kordower, J. H.; Mufson, E. J. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol., 2002, 51(2), 145-155.
15. Mesulam, M. M.; Mufson, E. J.; Levey, A. I.; Wainer, B. H. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Comp Neurol., 1983, 214(2), 170-197.
16. Mesulam, M. M., Geula, C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J. Comp Neurol., 1988, 275(2), 216-240.
17. Coyle, J. T.; Price, D. L.; DeLong, M. R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science, 1983, 219(4589), 1184-1190.
18. Sarter, M., Bruno, J. P. Developmental origins of the age-related decline in cortical cholinergic function and associated cognitive abilities. Neurobiol. Aging, 2004, 25(9), 1127-1139.
19. Mandel, R. J., Thal, L. J. Physostigmine improves water maze performance following nucleus basalis magnocellularis lesions in rats. Psychopharmacology (Berl), 1988, 96(3), 421-425.
20. Dekker, A. J.; Connor, D. J.; Thal, L. J. The role of cholinergic projections from the nucleus basalis in memory. Neurosci. Biobehav. Rev., 1991, 15(2), 299-317.
21. Ridley, R. M.; Barratt, N. G.; Baker, H. F. Cholinergic learning deficits in the marmoset produced by scopolamine and ICV hemicholinium. Psychopharmacology (Berl), 1984, 83(4), 340-345.
22. Ridley, R. M.; Murray, T. K.; Johnson, J. A.; Baker, H. F. Learning impairment following lesion of the basal nucleus of Meynert in the marmoset: modification by cholinergic drugs. Brain Res., 1986, 376(1), 108-116.
23. Crow, T. J., Grove-White, I. G. An analysis of the learning deficit following hyoscine administration to man. Br. J. Pharmacol., 1973, 49(2), 322-327.
24. Bartus, R. T.; Dean, R. L., III; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science, 1982, 217(4558), 408-414.
25. Wilkinson, D. Pharmacological treatment of Alzheimer's disease in Oxford Neurology Library: Alzheimer's disease. Eds. Waldemar and Burns 2009, 57-65.
26. Nyakas C., Granic I., Halmy L. G., Banerjee P., Luiten P. G. The Basal Forebrain Cholinergic System in Ageing and Dementia. Rescuing Cholinergic Neurons from Neurotoxic Amyloid-beta42 with Memantine. Behav. Brain Res., 2011; 221(2): 594-603.
27. Vassar, R.; Bennett, B. D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E. A.; Denis, P.; Teplow, D. B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M. A.; Biere, A. L.; Curran, E.; Burgess, T.; Louis, J. C.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 1999, 286(5440), 735-741.
28. Wolfe, M. S.; Xia, W.; Ostaszewski, B. L.; Diehl, T. S.; Kimberly, W. T.; Selkoe, D. J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature, 1999, 398(6727), 513-517.
29. Francis, R.; McGrath, G.; Zhang, J.; Ruddy, D. A.; Sym, M.; Apfeld, J.; Nicoll, M.; Maxwell, M.; Hai, B.; Ellis, M. C.; Parks, A. L.; Xu, W.; Li, J.; Gurney, M.; Myers, R. L.; Himes, C. S.; Hiebsch, R.; Ruble, C.; Nye, J. S.; Curtis, D. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev. Cell, 2002, 3(1), 85-97.
30. Selkoe, D. J. The molecular pathology of Alzheimer's disease. Neuron, 1991, 6(4), 487-498.
31. Hardy, J. A., Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256(5054), 184-185.
32. Muirhead, K. E.; Borger, E.; Aitken, L.; Conway, S. J.; Gunn Moore, F. J. The consequences of mitochondrial amyloid betapeptide in Alzheimer's disease. Biochem. J., 2010, 426(3), 255-270.
33. Su, B.; Wang, X.; Nunomura, A.; Moreira, P. I.; Lee, H. G.; Perry, G.; Smith, M. A.; Zhu, X. Oxidative stress signaling in Alzheimer's disease. Curr. Alzheimer Res., 2008, 5(6), 525-532.
34. Esch, F. S.; Keim, P. S.; Beattie, E. C.; Blacher, R. W.; Culwell, A. R.; Oltersdorf, T.; McClure, D.; Ward, P. J. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science, 1990, 248(4959), 1122-1124.
35. Buxbaum, J. D.; Liu, K. N.; Luo, Y.; Slack, J. L.; Stocking, K. L.; Peschon, J. J.; Johnson, R. S.; Castner, B. J.; Cerretti, D. P.; Black, R. A. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem., 1998, 273(43), 27765 27767.
36. Tyler, S. J.; Dawbarn, D.; Wilcock, G. K.; Allen, S. J. alpha and beta-secretase: profound changes in Alzheimer's disease. Biochem. Biophys. Res. Commun., 2002, 299(3), 373-376.
37. Cappai, R. and Barnham, K. J. Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. Neurochem. Res., 2008, 33(3), 526-532.
38. Yaar, M.; Zhai, S.; Fine, R. E.; Eisenhauer, P. B.; Arble, B. L.; Stewart, K. B.; Gilchrest, B. A. Amyloid beta binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling. J. Biol. Chem., 2002, 277(10), 7720-7725.
39. Iqbal, K.; Alonso, A. C.; Gong, C. X.; Khatoon, S.; Pei, J. J.; Wang, J. Z.; Grundke-Iqbal, I. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. J. Neural Transm. Suppl., 1998, 53, 169-180.
40. Gotz, J.; Chen, F.; van Dorpe, J.; Nitsch, R. M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science, 2001, 293(5534), 1491-1495.
41. Wilcock, G. K., Esiri, M. M. Plaques, tangles and dementia. A quantitative study. J. Neurol. Sci., 1982, 56(2-3), 343-356.
42. Appel, S. H. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann. Neurol., 1981, 10(6), 499-505.
43. Korsching, S.; Auburger, G.; Heumann, R.; Scott, J.; Thoenen, H. Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. EMBO J., 1985, 4(6), 1389-1393.
44. Seiler, M., Schwab, M. E. Specific retrograde transport of nerve growth factor (NGF) from neocortex to nucleus basalis in the rat. Brain Res., 1984, 300(1), 33-39.
45. Chao, M. V.; Bothwell, M. A.; Ross, A. H.; Koprowski, H.; Lanahan, A. A.; Buck, C. R.; Sehgal, A. Gene transfer and molecular cloning of the human NGF receptor. Science, 1986, 232(4749), 518-521.
46. Kaplan, D. R., Miller, F. D. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol., 2000, 10(3), 381-391.
47. Nykjaer, A.; Lee, R.; Teng, K. K.; Jansen, P.; Madsen, P.; Nielsen, M. S.; Jacobsen, C.; Kliemannel, M.; Schwarz, E.; Willnow, T. E.; Hempstead, B. L.; Petersen, C. M. Sortilin is essential for proNGFinduced neuronal cell death. Nature, 2004, 427(6977), 843-848.
48. Kaplan, D. R.; Hempstead, B. L.; Martin-Zanca, D.; Chao, M. V.; Parada, L. F. The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science, 1991, 252(5005), 554 558.
49. Riopelle, R. J.; Richardson, P. M.; Verge, V. M. Distribution and characteristics of nerve growth factor binding on cholinergic neurons of rat and monkey forebrain. Neurochem. Res., 1987, 12(10), 923-928.
50. Dawbarn, D.; Allen, S. J.; Semenenko, F. M. Coexistence of choline acetyltransferase and nerve growth factor receptors in the rat basal forebrain. Neurosci. Lett., 1988, 94(1-2), 138-144.
51. Dawbarn, D.; Allen, S. J.; Semenenko, F. M. Immunohistochemical localization of beta-nerve growth factor receptors in the forebrain of the rat. Brain Res., 1988, 440(1), 185-189.
52. Kordower, J. H.; Bartus, R. T.; Bothwell, M.; Schatteman, G.; Gash, D. M. Nerve growth factor receptor immunoreactivity in the nonhuman primate (Cebus apella): distribution, morphology, and colocalization with cholinergic enzymes. J. Comp Neurol., 1988, 277(4), 465-486.
53. Schatteman, G. C.; Gibbs, L.; Lanahan, A. A.; Claude, P.; Bothwell, M. Expression of NGF receptor in the developing and adult primate central nervous system. J. Neurosci., 1988, 8(3), 860-873.
54. Allen, S. J.; Dawbarn, D.; Spillantini, M. G.; Goedert, M.; Wilcock, G. K.; Moss, T. H.; Semenenko, F. M. Distribution of betanerve growth factor receptors in the human basal forebrain. J. Comp. Neurol., 1989, 289(4), 626-640.
55. Steininger, T. L.; Wainer, B. H.; Klein, R.; Barbacid, M.; Palfrey, H. C. High-affinity nerve growth factor receptor (Trk) immunoreactivity is localized in cholinergic neurons of the basal forebrain and striatum in the adult rat brain. Brain Res., 1993, 612(1-2), 330-335.
56. Sobreviela, T.; Clary, D. O.; Reichardt, L. F.; Brandabur, M. M.; Kordower, J. H.; Mufson, E. J. TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. J. Comp Neurol., 1994, 350(4), 587-611.
57. Whitehouse, P. J.; Price, D. L.; Clark, A. W.; Coyle, J. T.; DeLong, M. R. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol., 1981, 10(2), 122-126.
58. Allen, S.; Dawbarn, D.; MacGowan, S.; Wilcock, G.; Treanor, J.; Moss, T. A Quantitative morphometric analysis of basal forebrain neurons expressing-NGF receptors in normal and Alzheimer's disease brains. Dementia, 1990, 1, 125-137.
59. Allen, S.; Treanor, J.; MacGowan, S.; Wilcock, G.; Dawbarn, D. Distribution and characterisation of DD-nerve growth factor receptors in Alzheimer's disease. In Growth factors and Alzheimer's disease. Hefti, F.; brachet, P., Will, B., Christen, Y., Eds. Springer Verlag. 1991, pp. 81-97.
60. Hefti, F., Mash, D. C. Localization of nerve growth factor receptors in the normal human brain and in Alzheimer's disease. Neurobiol. Aging, 1989, 10(1), 75-87.
61. Mufson, E. J.; Bothwell, M.; Kordower, J. H. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain. Exp. Neurol., 1989, 105(3), 221-232.
62. Goedert, M.; Fine, A.; Hunt, S. P.; Ullrich, A. Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in Alzheimer's disease. Brain Res., 1986, 387(1), 85-92.
63. Allen, S. J.; MacGowan, S. H.; Treanor, J. J.; Feeney, R.; Wilcock, G. K.; Dawbarn, D. Normal beta-NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci. Lett., 1991, 131(1), 135-139.
64. Crutcher, K. A.; Scott, S. A.; Liang, S.; Everson, W. V.; Weingartner, J. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J. Neurosci., 1993, 13(6), 2540-2550.
65. Mufson, E. J.; Conner, J. M.; Kordower, J. H. Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. Neuroreport, 1995, 6(7), 1063-1066.
66. Cooper, J. D.; Salehi, A.; Delcroix, J. D.; Howe, C. L.; Belichenko, P. V.; Chua-Couzens, J.; Kilbridge, J. F.; Carlson, E. J.; Epstein, C. J.; Mobley, W. C. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc. Natl. Acad. Sci. USA, 2001, 98(18), 10439-10444.
67. Salehi, A.; Delcroix, J. D.; Belichenko, P. V.; Zhan, K.; Wu, C.; Valletta, J. S.; Takimoto-Kimura, R.; Kleschevnikov, A. M.; Sambamurti, K.; Chung, P. P.; Xia, W.; Villar, A.; Campbell, W. A.; Kulnane, L. S.; Nixon, R. A.; Lamb, B. T.; Epstein, C. J.; Stokin, G. B.; Goldstein, L. S.; Mobley, W. C. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron, 2006, 51(1), 29 42.
68. Kaplan, D. R., Miller, F. D. Neurobiology: a move to sort life from death. Nature, 2004, 427(6977), 798-799.
69. Mufson, E. J.; Ma, S. Y.; Cochran, E. J.; Bennett, D. A.; Beckett, L. A.; Jaffar, S.; Saragovi, H. U.; Kordower, J. H. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J. Comp. Neurol., 2000, 427(1), 19-30.
70. Ginsberg, S. D.; Che, S.; Counts, S. E.; Mufson, E. J. Single cell gene expression profiling in Alzheimer's disease. NeuroRx., 2006, 3(3), 302-318.
71. Ginsberg, S. D.; Che, S.; Wuu, J.; Counts, S. E.; Mufson, E. J. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J. Neurochem., 2006, 97(2), 475-487.
72. Goedert, M.; Fine, A.; Dawbarn, D.; Wilcock, G. K.; Chao, M. V. Nerve growth factor receptor mRNA distribution in human brain: normal levels in basal forebrain in Alzheimer's disease. Brain Res. Mol. Brain Res., 1989, 5(1), 1-7.
73. Treanor, J. J.; Dawbarn, D.; Allen, S. J.; MacGowan, S. H.; Wilcock, G. K. Low affinity nerve growth factor receptor binding in normal and Alzheimer's disease basal forebrain. Neurosci. Lett., 1991, 121(1-2), 73-76.
74. Fahnestock, M.; Michalski, B.; Xu, B.; Coughlin, M. D. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol. Cell Neurosci., 2001, 18(2), 210-220.
75. Peng, S.; Wuu, J.; Mufson, E. J.; Fahnestock, M. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J. Neuropathol. Exp. Neurol., 2004, 63(6), 641 649.
76. Debeir, T.; Saragovi, H. U.; Cuello, A. C. A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat. Proc. Natl. Acad. Sci. USA, 1999, 96(7), 4067-4072.
77. Cuello, A. C.; Bruno, M. A.; Allard, S.; Leon, W.; Iulita, M. F. Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation. J. Mol. Neurosci., 2010, 40(1-2), 230 235.
78. Bruno, M. A., Cuello, A. C. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc. Natl. Acad. Sci. USA, 2006, 103(17), 6735-6740.
79. Fabbro, S., Seeds, N. W. Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. J. Neurochem., 2009, 109(2), 303-315.
80. Barker, P. A. p75NTR is positively promiscuous: novel partners and new insights. Neuron, 2004, 42(4), 529-533.
81. Lee, R.; Kermani, P.; Teng, K. K.; Hempstead, B. L. Regulation of cell survival by secreted proneurotrophins. Science, 2001, 294(5548), 1945-1948.
82. Clewes, O.; Fahey, M. S.; Tyler, S. J.; Watson, J. J.; Seok, H.; Catania, C.; Cho, K.; Dawbarn, D.; Allen, S. J. Human ProNGF: biological effects and binding profiles at TrkA, P75NTR and sortilin. J. Neurochem., 2008, 107(4), 1124-1135.
83. Masoudi, R.; Ioannou, M. S.; Coughlin, M. D.; Pagadala, P.; Neet, K. E.; Clewes, O.; Allen, S. J.; Dawbarn, D.; Fahnestock, M. Biological activity of nerve growth factor precursor is dependent upon relative levels of its receptors. J. Biol. Chem., 2009, 284(27), 18424-18433.
84. Fahnestock, M.; Yu, G.; Michalski, B.; Mathew, S.; Colquhoun, A.; Ross, G. M.; Coughlin, M. D. The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor. J. Neurochem., 2004, 89(3), 581-592.
85. Kim, T., Hempstead, B. L. NRH2 is a trafficking switch to regulate sortilin localization and permit proneurotrophin-induced cell death. EMBO J., 2009, 28(11), 1612-1623.
86. Kenchappa, R. S.; Zampieri, N.; Chao, M. V.; Barker, P. A.; Teng, H. K.; Hempstead, B. L.; Carter, B. D. Ligand-dependent cleavage of the P75 neurotrophin receptor is necessary for NRIF nuclear translocation and apoptosis in sympathetic neurons. Neuron, 2006, 50(2), 219-232.
87. Salehi, A. H.; Xanthoudakis, S.; Barker, P. A. NRAGE, a p75 neurotrophin receptor-interacting protein, induces caspase activation and cell death through a JNK-dependent mitochondrial pathway. J. Biol. Chem., 2002, 277(50), 48043-48050.
88. Mufson, E. J.; Wuu, J.; Counts, S. E.; Nykjaer, A. Preservation of cortical sortilin protein levels in MCI and Alzheimer's disease. Neurosci. Lett., 2010, 471(3), 129-133.
89. Jansen, P.; Giehl, K.; Nyengaard, J. R.; Teng, K.; Lioubinski, O.; Sjoegaard, S. S.; Breiderhoff, T.; Gotthardt, M.; Lin, F.; Eilers, A.; Petersen, C. M.; Lewin, G. R.; Hempstead, B. L.; Willnow, T. E.; Nykjaer, A. Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury. Nat. Neurosci., 2007, 10(11), 1449-1457.
90. Al Shawi, R.; Hafner, A.; Olsen, J.; Chun, S.; Raza, S.; Thrasivoulou, C.; Lovestone, S.; Killick, R.; Simons, P.; Cowen, T. Neurotoxic and neurotrophic roles of proNGF and the receptor sortilin in the adult and ageing nervous system. Eur. J. Neurosci., 2008, 27(8), 2103-2114.
91. Al Shawi, R.; Hafner, A.; Chun, S.; Raza, S.; Crutcher, K.; Thrasivoulou, C.; Simons, P.; Cowen, T. ProNGF, sortilin, and agerelated neurodegeneration. Ann. N. Y. Acad. Sci., 2007, 1119, 208 215.
92. Phillips, H. S.; Hains, J. M.; Laramee, G. R.; Rosenthal, A.; Winslow, J. W. Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons. Science, 1990, 250(4978), 290-294.
93. Wetmore, C.; Ernfors, P.; Persson, H.; Olson, L. Localization of brain-derived neurotrophic factor mRNA to neurons in the brain by in situ hybridization. Exp. Neurol., 1990, 109(2), 141-152.
94. Ghosh, A.; Carnahan, J.; Greenberg, M. E. Requirement for BDNF in activity-dependent survival of cortical neurons. Science, 1994, 263(5153), 1618-1623.
95. Lindholm, D.; Carroll, P.; Tzimagiogis, G.; Thoenen, H. Autocrineparacrine regulation of hippocampal neuron survival by IGF-1 and the neurotrophins BDNF, NT-3 and NT-4. Eur. J. Neurosci., 1996, 8(7), 1452-1460.
96. Alderson, R. F.; Alterman, A. L.; Barde, Y. A.; Lindsay, R. M. Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron, 1990, 5(3), 297-306.
97. Hyman, C.; Hofer, M.; Barde, Y. A.; Juhasz, M.; Yancopoulos, G. D.; Squinto, S. P.; Lindsay, R. M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature, 1991, 350(6315), 230-232.
98. Zuccato, C. and Cattaneo, E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol., 2009, 5(6), 311-322.
99. Brunoni, A. R.; Lopes, M.; Fregni, F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int. J. Neuropsychopharmacol., 2008, 11(8), 1169-1180.
100. Xiu, M. H.; Hui, L.; Dang, Y. F.; Hou, T. D.; Zhang, C. X.; Zheng, Y. L.; Chen, d. C.; Kosten, T. R.; Zhang, X. Y. Decreased serum BDNF levels in chronic institutionalized schizophrenia on longterm treatment with typical and atypical antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33(8), 1508-1512.
101. Zeev, B. B.; Bebbington, A.; Ho, G.; Leonard, H.; de Klerk, N.; Gak, E.; Vecsler, M.; Christodoulou, J. The common BDNF polymorphism may be a modifier of disease severity in Rett syndrome. Neurology, 2009, 72(14), 1242-1247.
102. Bliss, T. V., Lomo, T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J. Physiol., 1973, 232(2), 331 356.
103. Bliss, T. V., Collingridge, G. L. A synaptic model of memory: longterm potentiation in the hippocampus. Nature, 1993, 361(6407), 31-39.
104. Lu, Y.; Christian, K.; Lu, B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol. Learn. Mem., 2008, 89(3), 312-323.
105. Figurov, A.; Pozzo-Miller, L. D.; Olafsson, P.; Wang, T.; Lu, B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature, 1996, 381(6584), 706-709.
106. Frey, U.; Krug, M.; Reymann, K. G.; Matthies, H. Anisomycin, an inhibitor of protein synthesis, blocks late phases of LTP phenomena in the hippocampal CA1 region in vitro. Brain Res., 1988, 452(1-2), 57-65.
107. Dragunow, M.; Beilharz, E.; Mason, B.; Lawlor, P.; Abraham, W.; Gluckman, P. Brain-derived neurotrophic factor expression after long-term potentiation. Neurosci. Lett., 1993, 160(2), 232-236.
108. Drake, C. T.; Milner, T. A.; Patterson, S. L. Ultrastructural localization of full-length trkB immunoreactivity in rat hippocampus suggests multiple roles in modulating activity-dependent synaptic plasticity. J. Neurosci., 1999, 19(18), 8009-8026.
109. Yoshii, A., Constantine-Paton, M. BDNF induces transport of PSD-95 to dendrites through PI3K-AKT signaling after NMDA receptor activation. Nat. Neurosci., 2007, 10(6), 702-711.
110. Ma, Y. L.; Wang, H. L.; Wu, H. C.; Wei, C. L.; Lee, E. H. Brainderived neurotrophic factor antisense oligonucleotide impairs memory retention and inhibits long-term potentiation in rats. Neuroscience, 1998, 82(4), 957-967.
111. Mizuno, M.; Yamada, K.; Olariu, A.; Nawa, H.; Nabeshima, T. Involvement of brain-derived neurotrophic factor in spatial memory formation and maintenance in a radial arm maze test in rats. J. Neurosci., 2000, 20(18), 7116-7121.
112. Mu, J. S.; Li, W. P.; Yao, Z. B.; Zhou, X. F. Deprivation of endogenous brain-derived neurotrophic factor results in impairment of spatial learning and memory in adult rats. Brain Res., 1999, 835(2), 259-265.
113. Korte, M.; Carroll, P.; Wolf, E.; Brem, G.; Thoenen, H.; Bonhoeffer, T. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc. Natl. Acad. Sci. USA, 1995, 92(19), 8856-8860.
114. Pang, P. T., Lu, B. Regulation of late-phase LTP and long-term memory in normal and aging hippocampus: role of secreted proteins tPA and BDNF. Ageing Res. Rev., 2004, 3(4), 407-430.
115. Linnarsson, S.; Bjorklund, A.; Ernfors, P. Learning deficit in BDNF mutant mice. Eur. J. Neurosci., 1997, 9(12), 2581-2587.
116. Martinez, A.; Alcantara, S.; Borrell, V.; Del Rio, J. A.; Blasi, J.; Otal, R.; Campos, N.; Boronat, A.; Barbacid, M.; Silos-Santiago, I.; Soriano, E. TrkB and TrkC signaling are required for maturation and synaptogenesis of hippocampal connections. J. Neurosci., 1998, 18(18), 7336-7350.
117. Korte, M.; Griesbeck, O.; Gravel, C.; Carroll, P.; Staiger, V.; Thoenen, H.; Bonhoeffer, T. Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brainderived neurotrophic factor mutant mice. Proc. Natl. Acad. Sci. USA, 1996, 93(22), 12547-12552.
118. Kang, H.; Welcher, A. A.; Shelton, D.; Schuman, E. M. Neurotrophins and time: different roles for TrkB signaling in hippocampal long-term potentiation. Neuron, 1997, 19(3), 653-664.
119. Minichiello, L.; Korte, M.; Wolfer, D.; Kuhn, R.; Unsicker, K.; Cestari, V.; Rossi-Arnaud, C.; Lipp, H. P.; Bonhoeffer, T.; Klein, R. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron, 1999, 24(2), 401-414.
120. Saarelainen, T.; Pussinen, R.; Koponen, E.; Alhonen, L.; Wong, G.; Sirvio, J.; Castren, E. Transgenic mice overexpressing truncated trkB neurotrophin receptors in neurons have impaired long-term spatial memory but normal hippocampal LTP. Synapse, 2000, 38(1), 102-104.
121. Blitzer, R. D.; Iyengar, R.; Landau, E. M. Postsynaptic signaling networks: cellular cogwheels underlying long-term plasticity. Biol. Psychiatry, 2005, 57(2), 113-119.
122. Bramham, C. R., Srebro, B. Induction of long-term depression and potentiation by low and high-frequency stimulation in the dentate area of the anesthetized rat: magnitude, time course and EEG. Brain Res., 1987, 405(1), 100-107.
123. Woo, N. H.; Teng, H. K.; Siao, C. J.; Chiaruttini, C.; Pang, P. T.; Milner, T. A.; Hempstead, B. L.; Lu, B. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat. Neurosci., 2005, 8(8), 1069-1077.
124. Pozzo-Miller, L. D.; Gottschalk, W.; Zhang, L.; McDermott, K.; Du, J.; Gopalakrishnan, R.; Oho, C.; Sheng, Z. H.; Lu, B. Impairments in high-frequency transmission, synaptic vesicle docking, and synaptic protein distribution in the hippocampus of BDNF knockout mice. J. Neurosci., 1999, 19(12), 4972-4983.
125. Yang, J.; Siao, C. J.; Nagappan, G.; Marinic, T.; Jing, D.; McGrath, K.; Chen, Z. Y.; Mark, W.; Tessarollo, L.; Lee, F. S.; Lu, B.; Hempstead, B. L. Neuronal release of proBDNF. Nat. Neurosci., 2009, 12(2), 113-115.
126. Matsumoto, T.; Rauskolb, S.; Polack, M.; Klose, J.; Kolbeck, R.; Korte, M.; Barde, Y. A. Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat. Neurosci., 2008, 11(2), 131-133.
127. Barker, P. A. Whither proBDNF? Nat. Neurosci., 2009, 12(2), 105 106.
128. Goodman, L. J.; Valverde, J.; Lim, F.; Geschwind, M. D.; Federoff, H. J.; Geller, A. I.; Hefti, F. Regulated release and polarized localization of brain-derived neurotrophic factor in hippocampal neurons. Mol. Cell Neurosci., 1996, 7(3), 222-238.
129. Mowla, S. J.; Pareek, S.; Farhadi, H. F.; Petrecca, K.; Fawcett, J. P.; Seidah, N. G.; Morris, S. J.; Sossin, W. S.; Murphy, R. A. Differential sorting of nerve growth factor and brain-derived neurotrophic factor in hippocampal neurons. J. Neurosci., 1999, 19(6), 2069-2080.
130. Lou, H.; Kim, S. K.; Zaitsev, E.; Snell, C. R.; Lu, B.; Loh, Y. P. Sorting and activity-dependent secretion of BDNF require interaction of a specific motif with the sorting receptor carboxypeptidase e. Neuron, 2005, 45(2), 245-255.
131. Chen, Z. Y.; Ieraci, A.; Teng, H.; Dall, H.; Meng, C. X.; Herrera, D. G.; Nykjaer, A.; Hempstead, B. L.; Lee, F. S. Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway. J. Neurosci., 2005, 25(26), 6156 6166.
132. Gratacos, M.; Gonzalez, J. R.; Mercader, J. M.; de Cid, R.; Urretavizcaya, M.; Estivill, X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol. Psychiatry, 2007, 61(7), 911 922.
133. Egan, M. F.; Kojima, M.; Callicott, J. H.; Goldberg, T. E.; Kolachana, B. S.; Bertolino, A.; Zaitsev, E.; Gold, B.; Goldman, D.; Dean, M.; Lu, B.; Weinberger, D. R. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell, 2003, 112(2), 257 269.
134. Hariri, A. R.; Goldberg, T. E.; Mattay, V. S.; Kolachana, B. S.; Callicott, J. H.; Egan, M. F.; Weinberger, D. R. Brain-derived neurotrophic factor val66met polymorphism affects human memoryrelated hippocampal activity and predicts memory performance. J. Neurosci., 2003, 23(17), 6690-6694.
135. Pezawas, L.; Verchinski, B. A.; Mattay, V. S.; Callicott, J. H.; Kolachana, B. S.; Straub, R. E.; Egan, M. F.; Meyer-Lindenberg, A.; Weinberger, D. R. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J. Neurosci., 2004, 24(45), 10099-10102.
136. Karege, F.; Perret, G.; Bondolfi, G.; Schwald, M.; Bertschy, G.; Aubry, J. M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res., 2002, 109(2), 143-148.
137. Shimizu, E.; Hashimoto, K.; Okamura, N.; Koike, K.; Komatsu, N.; Kumakiri, C.; Nakazato, M.; Watanabe, H.; Shinoda, N.; Okada, S.; Iyo, M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry, 2003, 54(1), 70-75.
138. Mamounas, L. A.; Blue, M. E.; Siuciak, J. A.; Altar, C. A. Brainderived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J. Neurosci., 1995, 15(12), 7929 7939.
139. Russo-Neustadt, A.; Beard, R. C.; Cotman, C. W. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology, 1999, 21(5), 679-682.
140. Duman, R. S. and Vaidya, V. A. Molecular and cellular actions of chronic electroconvulsive seizures. J. ECT., 1998, 14(3), 181-193.
141. Zou, Y. F.; Ye, D. Q.; Feng, X. L.; Su, H.; Pan, F. M.; Liao, F. F. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur. Neuropsychopharmacol., 2010. [Epub ahead of print].
142. Phillips, H. S.; Hains, J. M.; Armanini, M.; Laramee, G. R.; Johnson, S. A.; Winslow, J. W. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron, 1991, 7(5), 695-702.
143. Holsinger, R. M.; Schnarr, J.; Henry, P.; Castelo, V. T.; Fahnestock, M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res. Mol. Brain Res., 2000, 76(2), 347-354.
144. Narisawa-Saito, M.; Wakabayashi, K.; Tsuji, S.; Takahashi, H.; Nawa, H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport, 1996, 7(18), 2925-2928.
145. Connor, B.; Young, D.; Yan, Q.; Faull, R. L.; Synek, B.; Dragunow, M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res. Mol. Brain Res., 1997, 49(1-2), 71-81.
146. Ferrer, I.; Marin, C.; Rey, M. J.; Ribalta, T.; Goutan, E.; Blanco, R.; Tolosa, E.; Marti, E. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J. Neuropathol. Exp. Neurol., 1999, 58(7), 729-739.
147. Savaskan, E.; Muller-Spahn, F.; Olivieri, G.; Bruttel, S.; Otten, U.; Rosenberg, C.; Hulette, C.; Hock, C. Alterations in trk A, trk B and trk C receptor immunoreactivities in parietal cortex and cerebellum in Alzheimer's disease. Eur. Neurol., 2000, 44(3), 172-180.
148. Peng, S.; Wuu, J.; Mufson, E. J.; Fahnestock, M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J. Neurochem., 2005, 93(6), 1412-1421.
149. Michalski, B., Fahnestock, M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Brain Res. Mol. Brain Res., 2003, 111(1-2), 148-154.
150. Fahnestock, M.; Garzon, D.; Holsinger, R. M.; Michalski, B. Neurotrophic factors and Alzheimer's disease: are we focusing on the wrong molecule? J. Neural Transm. Suppl., 2002,(62), 241 252.
151. Garzon, D.; Yu, G.; Fahnestock, M. A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. J. Neurochem., 2002, 82(5), 1058-1064.
152. Arancio, O., Chao, M. V. Neurotrophins, synaptic plasticity and dementia. Curr. Opin. Neurobiol., 2007, 17(3), 325-330.
153. Feher, A.; Juhasz, A.; Rimanoczy, A.; Kalman, J.; Janka, Z. Association between BDNF Val66Met polymorphism and Alzheimer disease, dementia with Lewy bodies, and Pick disease. Alzheimer Dis. Assoc. Disord., 2009, 23(3), 224-228.
154. Hashimoto, R.; Hirata, Y.; Asada, T.; Yamashita, F.; Nemoto, K.; Mori, T.; Moriguchi, Y.; Kunugi, H.; Arima, K.; Ohnishi, T. Effect of the brain-derived neurotrophic factor and the apolipoprotein E polymorphisms on disease progression in preclinical Alzheimer's disease. Genes Brain Behav., 2009, 8(1), 43-52.
155. Borroni, B.; Grassi, M.; Archetti, S.; Costanzi, C.; Bianchi, M.; Caimi, L.; Caltagirone, C.; Di Luca, M.; Padovani, A. BDNF genetic variations increase the risk of Alzheimer's disease-related depression. J. Alzheimers. Dis., 2009, 18(4), 867-875.
156. Salehi, A.; Verhaagen, J.; Dijkhuizen, P. A.; Swaab, D. F. Colocalization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Neuroscience, 1996, 75(2), 373-387.
157. Allen, S. J.; Wilcock, G. K.; Dawbarn, D. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease. Biochem. Biophys. Res. Commun., 1999, 264(3), 648-651.
158. Gnahn, H.; Hefti, F.; Heumann, R.; Schwab, M. E.; Thoenen, H. NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain? Brain Res., 1983, 285(1), 45-52.
159. Martinez, H. J.; Dreyfus, C. F.; Jonakait, G. M.; Black, I. B. Nerve growth factor selectively increases cholinergic markers but not neuropeptides in rat basal forebrain in culture. Brain Res., 1987, 412(2), 295-301.
160. Hartikka, J., Hefti, F. Comparison of nerve growth factor's effects on development of septum, striatum, and nucleus basalis cholinergic neurons in vitro. J. Neurosci. Res., 1988, 21(2-4), 352-364.
161. Hatanaka, H.; Nihonmatsu, I.; Tsukui, H. Nerve growth factor promotes survival of cultured magnocellular cholinergic neurons from nucleus basalis of Meynert in postnatal rats. Neurosci. Lett., 1988, 90(1-2), 63-68.
162. Haroutunian, V.; Kanof, P. D.; Davis, K. L. Partial reversal of lesion-induced deficits in cortical cholinergic markers by nerve growth factor. Brain Res., 1986, 386(1-2), 397-399.
163. Fischer, W.; Wictorin, K.; Bjorklund, A.; Williams, L. R.; Varon, S.; Gage, F. H. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature, 1987, 329(6134), 65-68.
164. Dekker, A. J., Thal, L. J. Effect of delayed treatment with nerve growth factor on choline acetyltransferase activity in the cortex of rats with lesions of the nucleus basalis magnocellularis: dose requirements. Brain Res., 1992, 584(1-2), 55-63.
165. Mandel, R. J.; Gage, F. H.; Thal, L. J. Spatial learning in rats: correlation with cortical choline acetyltransferase and improvement with NGF following NBM damage. Exp. Neurol., 1989, 104(3), 208-217.
166. Fischer, W.; Bjorklund, A.; Chen, K.; Gage, F. H. NGF improves spatial memory in aged rodents as a function of age. J. Neurosci., 1991, 11(7), 1889-1906.
167. Fischer, W.; Sirevaag, A.; Wiegand, S. J.; Lindsay, R. M.; Bjorklund, A. Reversal of spatial memory impairments in aged rats by nerve growth factor and neurotrophins 3 and 4/5 but not by brain-derived neurotrophic factor. Proc. Natl. Acad. Sci. USA, 1994, 91(18), 8607-8611.
168. Fischer, W. Nerve growth factor reverses spatial memory impairments in aged rats. Neurochem. Int., 1994, 25(1), 47-52.
169. Chen, K. S.; Nishimura, M. C.; Armanini, M. P.; Crowley, C.; Spencer, S. D.; Phillips, H. S. Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. J. Neurosci., 1997, 17(19), 7288-7296.
170. Capsoni, S.; Ugolini, G.; Comparini, A.; Ruberti, F.; Berardi, N.; Cattaneo, A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc. Natl. Acad. Sci. USA, 2000, 97(12), 6826-6831.
171. Capsoni, S.; Giannotta, S.; Cattaneo, A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. USA, 2002, 99(19), 12432-12437.
172. Olson, L.; Nordberg, A.; von Holst, H.; Backman, L.; Ebendal, T.; Alafuzoff, I.; Amberla, K.; Hartvig, P.; Herlitz, A.; Lilja, A.;. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J. Neural Transm. Park Dis. Dement. Sect., 1992, 4(1), 79-95.
173. Eriksdotter, J. M.; Nordberg, A.; Amberla, K.; Backman, L.; Ebendal, T.; Meyerson, B.; Olson, L.; Seiger; Shigeta, M.; Theodorsson, E.; Viitanen, M.; Winblad, B.; Wahlund, L. O. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 1998, 9(5), 246-257.
174. Winkler, J.; Ramirez, G. A.; Kuhn, H. G.; Peterson, D. A.; Day Lollini, P. A.; Stewart, G. R.; Tuszynski, M. H.; Gage, F. H.; Thal, L. J. Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann. Neurol., 1997, 41(1), 82-93.
175. Tuszynski, M. H.; Thal, L.; Pay, M.; Salmon, D. P.; HS, U.; Bakay, R.; Patel, P.; Blesch, A.; Vahlsing, H. L.; Ho, G.; Tong, G.; Potkin, S. G.; Fallon, J.; Hansen, L.; Mufson, E. J.; Kordower, J. H.; Gall, C.; Conner, J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med., 2005, 11(5), 551-555.
176. Tuszynski, M. H. Gene Therapy for Alzheimer's Disease Clinical Trial Updates. 2008, http://tuszynskilab. ucsd. edu/gt. php.
177. Mandel, R. J. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr. Opin. Mol. Ther., 2010, 12(2), 240-247.
178. Nagahara, A. H.; Merrill, D. A.; Coppola, G.; Tsukada, S.; Schroeder, B. E.; Shaked, G. M.; Wang, L.; Blesch, A.; Kim, A.; Conner, J. M.; Rockenstein, E.; Chao, M. V.; Koo, E. H.; Geschwind, D.; Masliah, E.; Chiba, A. A.; Tuszynski, M. H. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med., 2009, 15(3), 331-337.
179. Longo, F. M.; Yang, T.; Knowles, J. K.; Xie, Y.; Moore, L. A.; Massa, S. M. Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimer's disease mechanisms. Curr. Alzheimer Res., 2007, 4(5), 503-506.
180. Dawbarn, D.; Fahey, M.; Watson, J.; Tyler, S.; Shoemark, D.; Sessions, R.; Zhang, R.; Brady, L.; Willis, C.; Allen, S. J. NGF receptor TrkAd5: therapeutic agent and drug design target. Biochem. Soc. Trans., 2006, 34(Pt 4), 587-590.
181. Massa, S. M.; Yang, T.; Xie, Y.; Shi, J.; Bilgen, M.; Joyce, J. N.; Nehama, D.; Rajadas, J.; Longo, F. M. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J. Clin. Invest., 2010, 120(5), 1774-1785.